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By definition, about 2.5% of children show a short stature due to several causes. Two clinical conditions are characterized by serum
IGF-I low levels, idiopathic GH deficiency (IGHD), and GH insensitivity (GHI), and the phenotypic appearance of these patients
may be very similar. We studied two children with short stature and similar phenotypes.*e first case showed frontal bossing, doll
face, acromicria, and truncal obesity, with a GH peak <0.05 ng/ml after stimuli and undetectable serum IGF-I levels. After PCR
amplification of the whole GH1 gene, type IA idiopathic GHD was diagnosed. *e second case had cranium hypoplasia, a large
head, protruding forehead, saddle nose, underdeveloped mandible, and a micropenis. Basal GH levels were high (28.4 ng/ml)
while serum IGF-I levels were low and unchangeable during the IGF-I generation test. Laron syndrome was confirmed after the
molecular analysis of the GH receptor (GHR) gene. IGHD type IA and Laron syndrome is characterized by opposite circulating
levels of GH, while both have reduced levels of IGF-I, with an overlapping clinical phenotype, lacking the effects of IGF-I on
cartilage. *ese classical cases show the importance of differential diagnosis in children with severe short stature.
1. Introduction
By definition, about 2.5% of children show a short stature
due to several causes, including familiar background, genetic
and chromosomal abnormalities, hypothyroidism, and
chronic diseases such as celiac and Crohn’s disease [1].
Paediatric growth disease can also be secondary to
growth hormone-insulin-like growth factor-I (GH-IGF-I)
axis disorders, such as GH deficiency (GHD) or GH in-
sensitivity (GHI), both characterized by serum low levels of
IGF-I [2].
*e first approach to a short child is clinical and based on
the medical history and a physical examination focused on
finding abnormal signs and dysmorphic features. When all
other causes of short stature are excluded, the possibility of
GHD arises. *is is a rare condition with the prevalence
approximately of 1 : 4,000 children [3]. *e diagnosis must
be supported by biochemical and neuroradiological results, that
is, bluntedGH response to at least two pharmacological stimuli,
low concentration of IGF-I, and morphological abnormalities
of the hypothalamus-pituitary axis, respectively [4]. Moreover,
radiography of the left hand can indicate a delayed skeletal
maturation of the patient.
Another condition with serum low IGF-I levels is Laron
syndrome, the most common type of GH resistance. It is
caused by homozygous mutation of the GH receptor (GHR)
gene; the literature describes about 300–500 patients with
different mutations [5–7]. Diagnosis of Laron syndrome
must be supported by clinical and biochemical findings, such
as low IGF-I levels, which do not increase after exogenous
GH administration, elevated GH serum levels, and genetic
studies.
We studied two children with similar phenotypes and
severe short stature, but with different aetiology accounting
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for the short stature. erefore, the aim of the present study
was to identify the most reliable diagnostic parameters for
dierentiating children with comparable phenotypic
characteristics.
2. Case 1
e rst case was a South American small for gestational age
girl, born in the 41st week of gestation from non-
consanguineous parents, previously described by Keselman
et al. [8]. Neonatal auxological data are shown in Table 1.
At the age of 10 months, she showed frontal bossing, doll
face, acromicria, and truncal obesity (Figure 1(a)). Psy-
chomotor development was normal.
At 20 months of age, an endocrinological investiga-
tion was performed because of growth failure (Table 2).
An arginine test showed a very low response of GH se-
cretion, with a peak <0.05 ng/ml; IGF-I and IGF-binding
protein-3 (IGFBP-3) levels were undetectable (<25 ng/ml
and <0.5 μg/ml, resp. Table 3), while other pituitary hor-
mone (thyroid and adrenal function) levels were normal
(data not shown). A brain magnetic resonance imaging
(MRI) showed a severe anterior pituitary hypoplasia.
As a congenital GH gene abnormality was hypothe-
sized, a molecular characterization of GH1 gene was per-
formed; testing two genomic DNA samples by PCR
amplication of the whole GH1 gene did not yield any
product, suggesting a GH1 gene deletion. A subsequent
analysis conrmed the presence of two deletions of 6.7 and
7.6 kb. Based on these results, type IA IGHD was diagnosed
and the patient was started on rhGH replacement therapy
(0.33mg/kg/week).
3. Case 2
e second case was a Caucasian male, born at term by
caesarean section because of fetopelvic disproportion from
consanguineous parents (sons of rst cousins). Neonatal
auxological data are shown in Table 1. e perinatal period
was complicated by transient hypoglycaemia occurring on
the second day of life.
At 2.5 years, he showed cranium hypoplasia over the
splanchnocranium, a large head compared with the rest of
the body, a protruding forehead, depressed nasal bridge,
Table 1: Neonatal auxological parameters of the two patients.
Diagnosis Gestational age (weeks) Birth weight (kg) Head circumference (cm) Birth length (cm) Target height (cm)
GHD type IA 41 2.480 (−2.55 SDS) 34.1 (−0.42 SDS) 44.0 (−3.64 SDS) 153.5
Laron syndrome 39 3.350 (−0.30 SDS) 35.0 (0.18 SDS) 46.0 (−2.38 SDS) 163.5
Auxological parameters are expressed in SDS according to Bertino et al. [9].
Frontal bossing
Blue scleras
Saddle nose
maxillary hypoplasia
(a) (b)
Figure 1: Comparison of facial features of the two patients: (a) the GHD type IA patient and (b) the Laron syndrome patient.
Table 2: Auxological parameters of the two patients at the rst
endocrinological evaluation.
Diagnosis Age(yrs.)
Weight
(SDS)
Head
circumference
(SDS)
Height
(SDS)
BMI
(SDS)
GHD
type IA 0.8 −3.60 −2.00 −5.09 −7.12
Laron
syndrome 1.7 −4.60 −1.40 −6.10 0.12
Auxological parameters are expressed in SDS according to Cole et al. [10]
and WHO charts [11].
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underdeveloped mandible, and a micropenis (Figure 1(b)).
His auxological parameters are summarized in Table 2.
Because of growth retardation, he underwent an en-
docrinological evaluation. Basal GH levels were high
(28.4 ng/ml) and increased after an arginine infusion (GH
peak 67.1 ng/ml) suggesting a secretory hormone reserve. To
exclude a biological inactivity of GH, an IGF-I generation
test (three subcutaneous GH injections, 2 IU/day) was
requested. *e lack of increase in serum IGF-I values (basal
levels: 48 ng/ml) after GH administration (peak: 51 ng/ml,
Table 3) excluded a condition of GH bioinactivity suggesting
a condition of GH insensitivity. High basal serum GH
concentrations required a cerebral magnetic resonance
imaging of the hypothalamus-pituitary region to exclude
a pituitary neoplasia such as adenoma. All these results
suggested a GH insensitivity syndrome. Amolecular analysis
of the GHR gene showed a W80X homozygous mutation of
exon 5, of which his parents were both heterozygous carriers;
this mutation usually causes a premature stop codon,
resulting in a nonfunctional protein. *erefore, Laron
syndrome was confirmed and the patient was administered
a therapy with IGF-I (subcutaneous injections of doses up to
0.20mg/kg/day), reaching a final stature of 135 cm.
4. Discussion
*e phenotypic appearance of patients with complete GHD or
GHI may be very similar since in both conditions a reduction
or absence of the biological effects of GH is observed [12].
Patients with congenital isolated GHD have postnatal
severe growth retardation in early infancy (during or after
the first year of age) and a markedly short stature in
adulthood. *ese children may show facial dysmorphisms
such as craniofacial disproportion with hypoplasia of the
midface, frontal bossing, doll face, and sparse and fine hair.
*eir phenotype also includes truncal obesity, acromicria,
high-pitched voice, delayed skeletal maturation and denti-
tion, and genital abnormalities like micropenis and delayed
puberty [8, 13]. Similarly, patients with GHI syndrome show
reduced birth length and intrauterine growth retardation
and severe postnatal growth failure and short stature in
adulthood. During childhood, patients generally show
sparse hair, frontal bossing, saddle nose, shallow orbit, blue
sclera, high-pitched voice, delayed dentition, genital ab-
normalities, sleep disorders, severe short stature, obesity,
and delayed puberty [6, 13, 14].
As far as biochemical parameters are concerned, GHD
is characterized by low-circulating GH and IGF-I levels,
and IGF-II, IGFBP-3, and ALS reduction, reflecting their
GH-dependent status [13].
In GHI, as in GHD, markedly reduced IGF-I, IGF-II,
IGFBP3, and ALS levels are associated with normal or el-
evated serum GH levels, reflecting altered hypothalamic
feedback [14].
As the two syndromes are characterized by opposite
circulating levels of GH while both have reduced levels of
IGF-I, the phenotypic appearance of GHI and GHD is most
likely determined by the effect of IGF-I on cartilage. In fact,
circulating IGF-I, primarily produced by the liver, and
IGFBP-3 serum levels reflect endogenous GH secretion; GH
also has direct effects independent of IGF-I, but systemic
IGF-I is the main actor in the ossification process. Moreover,
IGF-I bioactivity is modulated by circulating IGFBPs [15].
*e GH-IGF-I axis plays a well-known role in the en-
dochondral ossification of long bones and in determining
stature, while craniofacial and somatic development is less
dependent on GH action [16].
*e first case shows typical characteristics of GHD, in
particular, birth growth retardation with growth failure in
the first year of life, an absence of psychomotor delay,
truncal obesity, and facial dysmorphies such as midface
hypoplasia, doll face, and frontal bossing. An MRI showed
only an anterior pituitary hypoplasia, while those for pa-
tients with genetic GHD generally reveal a normal or hy-
poplastic pituitary gland without abnormalities of the
hypothalamus, pituitary dystopia, agenesis of the pituitary
gland, or thinning or interruption of the pituitary stalk [17].
Considering the severely short stature, defined as
a height more than 3 SD below the mean, it is mandatory to
consider investigating for GHD [18, 19]. We therefore
measured baseline values of IGF-I, GH, and other pituitary
hormones and evaluated GH secretion after two pharma-
cological stimuli. Our patient had undetectable baseline and
peak values of GH, low serum levels of IGF-I, normal levels
of other pituitary hormones, and low serum levels of
IGFBP-3, compatible with isolated GHD. To determine the
type of GHD, we also performed a genetic analysis that
allowed us to diagnose type IA GHD; therefore, substitution
therapy was initiated with rhGH. *e literature reports
a genotype/phenotype correlation in patients with IGHD
[20]; children with type IA IGHD may have birth short
length and neonatal hypoglycaemia along with undetectable
GH concentrations with severe growth failure in the first 6
months. In fact, our patient began to show a worsening of
growth in the first six months.
In the second case, the patient had a severe growth deficit
with typical facial dysmorphies and elevated GH serum
values. We assumed a GHI and an assay for basal IGF-I and
IGFBP-3 levels were performed, with results below the
normal range. Growth hormone insensitivity is a group of
Table 3: Biochemical parameters of the two patients at the time of diagnosis.
Diagnosis Basal GH (ng/ml) GH peak (ng/ml)after arginine Basal IGF-I (ng/ml)
IGF-I peak (ng/ml)
after GH IGFBP-3 (μg/ml)
GHD type IA <0.05 <0.05 <25.0 n.a. <0.5
Laron syndrome 28.4 67.1 48.0 51.0 0.5
n.a.: not available.
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pathologies characterized by short stature associated with
normal or elevated GH concentrations. Primary GH in-
sensitivity is caused by genetic disorders involving GHR or
its downstream mediators such as STAT5b, the IGF-
I/IGFBP3-stabilized acid labile subunit (ALS), IGF-I, or
the IGF-I receptor gene [21].*emost common type is Laron
syndrome, caused by homozygous mutation of the GHR
gene. In other cases, the IGF-I deficiency may be secondary
to chronic or inflammatory diseases or to malnutrition.
Although in all cases there is a low-circulating level of IGF-I,
the clinical phenotypes and biochemical characteristics
within the GH-resistant patients group vary considerably
from short stature to extreme failure growth.
Both of our patients showed an overlapping clinical
phenotype due to the absence of effects of IGF-I on cartilage
and an MRI without large abnormalities but contrasting
biochemical data, particularly for GH values. *erefore,
these classical cases of IGHD and Laron syndrome underline
the importance of investigating severe short stature even in
the absence of other symptoms in the neonatal age and
without alteration to the MRI.
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